Upadacitinib (Rinvoq, AbbVie) 15mg or 30mg cools vexing nighttime itch in people with moderate-to-severe atopic dermatitis (AD), according to new research presented at the American Academy of Dermatology’s annual meeting in San Diego.
When compared with AD patients taking placebo, patients with AD who were treated with upadacitinib spent more time with no/minimal nighttime itch and no/minimal sleep disturbance, the study showed.
The new research included integrated data from Measure Up 1 and Measure Up 2, two phase 3 studies looking at the efficacy and safety profile of upadacitinib 15mg and 30mg in adolescents and adults with moderate-to-severe AD.
During the 16 weeks, patients who received upadacitinib experienced cumulatively 5- to 7-fold more time spent with no/minimal nighttime itch and 4- to 6-fold more time spent with no/minimal sleep disturbance when compared with counterparts who received placebo, report researchers who were led by Andrew Blauvelt, MD, MBA, an Investigator at Oregon Medical Research Center in Portland. What’s more, treatment with upadacitinib15 mg or 30 mg resulted in greater proportions of days spent with optimal improvements in nighttime itch and sleep disturbance compared with placebo, the study showed.
